Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
US11684615B2 · kind B2 · utility
2Cited by
85References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 29, 2020 |
| Grant date | Jun 27, 2023 |
| Priority date | — |
| Expiry date | Oct 19, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.